OpenNashEarnings

Life Sciences · NYSE: WAT

Waters earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 8 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Waters is integrating the BD Biosciences and Diagnostic Solutions businesses ahead of schedule, launching FACSDiscover A7 and buying MOBILion Systems to enter proteomics, while raising full-year guidance.

Waters's legacy analytical business grew 9% in constant currency, led by chemistry consumables and LC-MS instruments. Management cited instrument replacement, GLP-1s, PFAS and India generics as drivers. In the acquired businesses, reagents accelerated, China local manufacturing restored growth in Biosciences, and the new FACSDiscover A7 flow cytometer launched late in the quarter. Net price realization reached 120bps.

Read the Q3 2026 summary →Q3 2026 slides (PDF) ↗

Quarters

KPI history

Revenue$1.8B+120.9% y/yQ3 2026
Q4 2024: $872.7MQ4 ’24$872.7MQ1 2025: $661.7MQ1 ’25$661.7MQ2 2025: $771.3MQ2 ’25$771.3MQ3 2025: $799.9MQ3 ’25$799.9MQ4 2025: $932.4MQ4 ’25$932.4MQ1 2026: $1.3BQ1 ’26$1.3BQ2 2026: $1.6BQ2 ’26$1.6BQ3 2026: $1.8BQ3 ’26$1.8B
Data
Q4 2024$872.7M
Q1 2025$661.7M
Q2 2025$771.3M
Q3 2025$799.9M
Q4 2025$932.4M
Q1 2026$1.3B
Q2 2026$1.6B
Q3 2026$1.8B
Diluted EPS (GAAP)$0.82−67.2% y/yQ3 2026
Q4 2024: $3.88Q4 ’24$3.88Q1 2025: $2.03Q1 ’25$2.03Q2 2025: $2.47Q2 ’25$2.47Q3 2025: $2.50Q3 ’25$2.50Q4 2025: $3.77Q4 ’25$3.77Q1 2026: -$0.87Q1 ’26-$0.87Q2 2026: -$1.39Q2 ’26-$1.39Q3 2026: $0.82Q3 ’26$0.82
Data
Q4 2024$3.88
Q1 2025$2.03
Q2 2025$2.47
Q3 2025$2.50
Q4 2025$3.77
Q1 2026-$0.87
Q2 2026-$1.39
Q3 2026$0.82

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin7.2%−16.8 pts y/yQ3 2026
Q4 2024: 33.5%Q4 ’2433.5%Q1 2025: 22.9%Q1 ’2522.9%Q2 2025: 24.4%Q2 ’2524.4%Q3 2025: 24.0%Q3 ’2524.0%Q4 2025: 29.0%Q4 ’2529.0%Q1 2026: -3.7%Q1 ’26-3.7%Q2 2026: -5.2%Q2 ’26-5.2%Q3 2026: 7.2%Q3 ’267.2%
Data
Q4 202433.5%
Q1 202522.9%
Q2 202524.4%
Q3 202524.0%
Q4 202529.0%
Q1 2026-3.7%
Q2 2026-5.2%
Q3 20267.2%
Free cash flow$54.0M−66.7% y/yQ3 2026
Q1 2025: $234.0MQ1 ’25$234.0MQ2 2025: $18.0MQ2 ’25$18.0MQ3 2025: $162.0MQ3 ’25$162.0MQ4 2025: $125.8MQ4 ’25$125.8MQ1 2026: -$42.0MQ1 ’26-$42.0MQ2 2026: $153.0MQ2 ’26$153.0MQ3 2026: $54.0MQ3 ’26$54.0M
Data
Q1 2025$234.0M
Q2 2025$18.0M
Q3 2025$162.0M
Q4 2025$125.8M
Q1 2026-$42.0M
Q2 2026$153.0M
Q3 2026$54.0M

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$872.7M$661.7M$771.3M$799.9M$932.4M$1.3B$1.6B$1.8B
Operating income$292.3M$151.7M$188.2M$192.1M$270.5M-$47.0M-$86.0M$128.0M
Operating margin33.5%22.9%24.4%24.0%29.0%-3.7%-5.2%7.2%
Net income$231.4Md$121.4M$147.1M$148.9M$225.6Md-$72.0M-$136.0M$81.0M
Diluted EPS$3.88$2.03$2.47$2.50$3.77-$0.87-$1.39$0.82
Operating cash flow$240.1Md$260.0M$41.0Md$187.0Md$164.6Md-$3.0M$201.0Md$117.0Md
Capital expenditure—$26.0M$23.0Md$25.0Md$38.7Md$39.0M$48.0Md$63.0Md
Free cash flow—$234.0M$18.0M$162.0M$125.8M-$42.0M$153.0M$54.0M
R&D expense$46.9M$46.6M$48.5M$53.6M$46.9M$96.0M$122.0M$106.0M

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings